Support

Support Options

Submit a Support Ticket

 

KIST/PU Theragnosis – A New Paradigm of Personalized Medicine

By Ick Chan Kwon

Center for Theragnosis, Biomedical Research Institute, KIST

Published on

Abstract

Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given genetic information. Therefore to step further for the future advancement of personalized medicine, we need to introduce a concept of therapeutics in Companion Diagnosis. Here, we introduce Theragnosis as a new paradigm of personalized medicine which includes both a real-time visualization of disease phenotypes and a novel adaptive design of therapeutics all together at the same time.

Approaches in combining these two important functionalities all together in a polymer nanoparticle are proposed in this presentation. Self-assembled and auto-quenched fluorescent nanoparticular probes have been designed to visualize target molecules, such as proteases and protein kinases. These nanoparticles can also serve as useful therapeutic tools with using novel drug delivery technologies. Moreover, it might be possible to evaluated therapeutic efficacies in real-time manner when therapeutic design shares principles of diagnostic imaging. Examples of theragnostic design of ‘dose- amplification’ will be introduced in this presentation.

Bio

Ick Chan Kwon Ick Chan Kwon was born in 1959 in Daegu, South Korea. He is currently the Head of the Center for Theragnosis in KIST. He received his Ph.D. in 1993 in pharmaceutics and pharmaceutical chemistry from the University of Utah in 1993. He serves as the president of the Korean Society of Molecular Imaging, as an Associate Editor of the Journal of Controlled Release, as an Asian Editor of the Journal of Biomedical Nanotechnology, and as a member of several editorial boards. His current research interests are targeted drug delivery with polymeric nanoparticles and the development of smart nanoplatforms for theranosis. He has published over 180 peer-reviewed papers and has given over 60 national and international invited lectures.

Sponsored by

References

  1. Kwangmeyung Kim, Jong Ho Kim, Hyungkyu Park, Yoo-Shin Kim, Kyeongsoon Park, Heayun Nam, Seulki Lee, Jae Hyung Park, Rang-Woon Park, In-San Kim, Kuiwon Choi, Sang Yoon Kim, Kinam Park, Ick Chan Kwon, “Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring”, Journal of Controlled Release, 146 (2) 219-227 (2010)
  2. HeebeomKoo, MyungSookHuh, In-CheolSun, Soon HongYuk, KwangmeyungKim, Ick ChanKwon,“In vivo targeted delivery of nanoparticles for theragnosis”, Accounts of Chemical Research, in press,doi:10.1021/ar2000138

Cite this work

Researchers should cite this work as follows:

  • Ick Chan Kwon (2011), "KIST/PU Theragnosis – A New Paradigm of Personalized Medicine," http://nanohub.org/resources/12649.

    BibTex | EndNote

Time

Location

Burton Morgan 121, Purdue University, West Lafayette, IN

Tags

No classroom usage data was found. You may need to enable JavaScript to view this data.

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.